Open access · CC-BY
via OpenAlex
Advances in Mesenchymal Stem Cell Therapy for Immune and Inflammatory Diseases: Use of Cell-Free Products and Human pluripotent Stem Cell-Derived Mesenchymal Stem Cells
Li‐Tzu Wang, Ko‐Jiunn Liu, Huey‐Kang Sytwu, Ming‐Shyen Yen, Betty Linju Yen
Stem Cells Translational Medicine · 2021 · ▲ 131 citations
Stem-cell exhaustion
Altered intercellular communication
Chronic inflammation
Stem-cell therapy
Human
Preclinical / animal
Review
Abstract
Mesenchymal stem cell therapy (MSCT) for immune and inflammatory diseases continues to be popular based on progressive accumulation of preclinical mechanistic evidence. This has led to further expansion in clinical indications from graft rejection, autoimmune diseases, and osteoarthritis, to inflammatory liver and pulmonary diseases including COVID-19. A clear trend is the shift from using autologous to allogeneic MSCs, which can be immediately available as off-the-shelf products. In addition, new products such as cell-free exosomes and human pluripotent stem cell (hPSC)-derived MSCs are exciting developments to further prevalent use. Increasing numbers of trials have now published results in which safety of MSCT has been largely demonstrated. While reports of therapeutic endpoints are still emerging, efficacy can be seen for specific indications-including graft-vs-host-disease, strongly Th17-mediated autoimmune diseases, and osteoarthritis-which are more robustly supported by mechanistic preclinical evidence. In this review, we update and discuss outcomes in current MSCT clinical trials for immune and inflammatory disease, as well as new innovation and emerging trends in the field.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- OpenAlex
- DOI
- 10.1002/sctm.21-0021
- Canonical
- link ↗
- Fetched
- 2026-10-10 MST
Cite this
APA
Wang, L., Liu, K., Sytwu, H., Yen, M., & Yen, B.L. (2021). Advances in Mesenchymal Stem Cell Therapy for Immune and Inflammatory Diseases: Use of Cell-Free Products and Human pluripotent Stem Cell-Derived Mesenchymal Stem Cells. <em>Stem Cells Translational Medicine</em>. https://doi.org/10.1002/sctm.21-0021
Vancouver
Wang L, Liu K, Sytwu H, Yen M, Yen BL. Advances in Mesenchymal Stem Cell Therapy for Immune and Inflammatory Diseases: Use of Cell-Free Products and Human pluripotent Stem Cell-Derived Mesenchymal Stem Cells. Stem Cells Translational Medicine. 2021. doi:10.1002/sctm.21-0021.
BibTeX
@article{litzu2021Advanc,
title = {Advances in Mesenchymal Stem Cell Therapy for Immune and Inflammatory Diseases: Use of Cell-Free Products and Human pluripotent Stem Cell-Derived Mesenchymal Stem Cells},
author = {Li‐Tzu Wang and Ko‐Jiunn Liu and Huey‐Kang Sytwu and Ming‐Shyen Yen and Betty Linju Yen},
journal = {Stem Cells Translational Medicine},
year = {2021},
doi = {10.1002/sctm.21-0021},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
Human Cell 2014
Open access · CC-BY
Mesenchymal stem cell therapy and acute graft-versus-host disease: a review
Journal of Cellular and Molecular Medicine 2008
Open access · OA
Mesenchymal stem cells and their use as cell replacement therapy and disease modelling tool
Stem Cells International 2016
Open access · CC-BY
Umbilical Cord as Prospective Source for Mesenchymal Stem Cell‐Based Therapy
Current Pharmaceutical Design 2013
Open access · OA
Mesenchymal Stem/Stromal Cells: A New ''Cells as Drugs'' Paradigm. Efficacy and Critical Aspects in Cell Therapy
Stem Cells Translational Medicine 2019
Open access · CC-BY
Trends in mesenchymal stem cell clinical trials 2004-2018: Is efficacy optimal in a narrow dose range?
Experimental Hematology 2004
Open access · OA